Antiviral Drugs for Cirrhosis and Hepatitis

Viruses are the intracellular parasites that depend on synthetic processes of host cells. They cannot be grown on ordinary medium. Special microscopes are needed to visualize their structure, which consists of Genome (genetic material consisting of DNA or RNA component but never both), Surrounding capsid –proteinaceous in structure, Envelope –protein bilayer. Hepatitis B virus (HBV) is an important cause of end-stage liver disease and hepatocellular carcinoma (HCC). The decision to treat is based on the activity of liver disease and HBV replication status, and the likelihood of a long-term benefit. Approved therapies include standard and pegylated interferon-alfa and nucleoside analogues: lamivudine, adefovir and entecavir. Even with successful therapy, patients remain at risk for reactivation of viral replication and require lifelong monitoring.

HBV in HBsAg-positive patients treated with allogeneic hematopoietic cell transplantation. Highly active antiretroviral therapy is initiated for decreasing mortality relating to HIV. Influenza can be type A, B or C depending upon type. Influenza A and B are more common.

  • Anti-retroviral agents
  • Antiviral Regimens
  • Anti-herpes virus agents
  • Anti influenza agents

Related Conference of Antiviral Drugs for Cirrhosis and Hepatitis

September 23-24, 2019

2nd World Summit on Liver Cirrhosis and Hepatitis

Tokyo, Japan
October 14-15, 2019

19th World Gastroenterologists Summit

Sydney, Australia
October 23-24, 2019

World Congress on Pancreatic Cancer and Liver Diseases

| Tokyo, Japan
November 18-19, 2019

20th World Congress on Gastroenterology

Rome, Italy
December 02-03, 2019

International Conference on Infectious Diseases in Gynecology and Obstetrics

| Radisson Hotel Narita | Tokyo, Japan
June 24-25, 2020

15th Euro-Global Gastroenterology Conference

Rome,Italy

Antiviral Drugs for Cirrhosis and Hepatitis Conference Speakers

Recommended Sessions

Related Journals

Are you interested in